Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.
about
Future prospects for contact factors as therapeutic targetsRole of plasma kallikrein in diabetes and metabolismFactor XI and contact activation as targets for antithrombotic therapyFactor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in MiceInhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking AntibodyInfluence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosisIn vivo roles of factor XII.A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factorThrombosis Prevention without Anticoagulation.Murine models in the evaluation of heparan sulfate-based anticoagulants.Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoproteinContact pathway of coagulation and inflammationDefective glycosylation of coagulation factor XII underlies hereditary angioedema type IIIInhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsisThe polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.The dimeric structure of factor XI and zymogen activationFactors XI and XII as Targets for New Anticoagulants.The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications.The effects of arterial flow on platelet activation, thrombus growth, and stabilization.Investigational anticoagulants for hematological conditions: a new generation of therapies.Role of the kallikrein-kinin system in traumatic brain injury.Factor XII: a novel target for safe prevention of thrombosis and inflammation.The initiation and effects of plasma contact activation: an overview.The hemostatic role of factor XI.The Story of Angioedema: from Quincke to Bradykinin.Factor XII: form determines function.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.Single-chain factor XII: a new form of activated factor XII.Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography.Emerging Therapies in Hereditary Angioedema.The Effects of the Contact Activation System on Hemorrhage.An Integrative Thrombosis Network: Visualization and Topological Analysis.Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.
P2860
Q26865096-1D2FFC71-386D-41CA-A26A-520298F03614Q27016431-499DA87A-56E8-4427-A21D-44A54CB70598Q27024190-90C54676-5007-4271-98C8-208933CCF843Q27314976-89FAF7AC-F1DB-4BD3-BE21-38C9317F1DC0Q27684478-80B08CCF-DD9F-47F8-9EC4-1E7273E685E1Q34291787-4777B90D-F87B-47CB-ABE3-206FB403E57AQ34300714-7CBBFE4D-35E0-457D-B8A7-C20D0397DCAAQ34402606-1E65A9EE-16E7-40EF-9F5E-9BFA241F2292Q35004987-3E1BA313-A510-4F21-BDE9-3782D632AE1EQ35104501-17385D0A-71B7-4334-92FD-1F5B0B5056F2Q35193770-E65DE9E0-AD4A-4104-B383-3BC876BC4A2EQ35206857-EB065C40-6FB3-4051-A37F-F7342F670AC4Q35561296-6CD5C546-069D-45BA-8DEA-16945088D683Q35575101-9B604DD6-4B7B-4EA8-A798-A9C15DAA461CQ35700453-9C46992B-7A5B-4054-898E-533D0E0135ACQ36010211-419A3314-4480-49E9-AE10-2D81A79B90D9Q36051099-ADD12F04-A2E2-4AD1-AA35-E3025A60C84AQ36596540-DD156720-1764-4B72-AB3E-C52D91D5A8C2Q36767718-95E52583-CF09-4682-ACFA-0CFA1AB7BBF3Q36833564-3E603D7E-92E4-4C09-9875-524B90771749Q37662547-DAEDDD7B-0446-4276-9E98-2E7D07F7AB21Q37690857-D97C811C-B728-43C3-9413-86B5E7F68B81Q38106013-12B1C498-3C17-4DB9-BB8D-2EEFC996774AQ38123237-7B7C1DE2-C3C9-4E43-A71B-36A8403174F3Q38269009-4F3C1664-8A59-4252-8DDB-6CFA13B2178CQ38587540-9C686500-E2E8-452F-81AB-57D1857751D5Q38795041-AAE3B3BC-3A36-4571-BD66-6FC40D520886Q38840382-D12BB827-70E2-4104-BBCB-F9FB42ED4000Q38855032-A7D19AC9-C86A-44A4-A0E0-C36FE67C3ED5Q38860396-F1628602-8D89-4C77-8AC8-575E3BF07479Q38956551-01106597-74BE-44E8-B666-8FA7044DA895Q38994649-05879E10-2669-49EB-B7E3-8D1339ECAA57Q39175404-E77059B6-FB69-4F3B-8DAC-DD65763A0343Q39366435-D47ACC41-9DB9-43E1-ACF5-555605E4B0C6Q39379451-0A904ECF-99FB-45EF-8751-85C1ECD40557Q39421468-CC4A0447-5CBD-43D4-8F26-52118319E7A5Q41171782-8B739F2B-1888-42A6-A21A-5747DEABCE6FQ41444600-142F6752-7031-4390-A839-418352982602Q42922540-819640F0-26BB-4AE3-87A8-D277391C5347Q43168936-5FD5C561-3DE0-41A6-AC80-D3AA5BFAC0E2
P2860
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Selective depletion of plasma ...... ut increased risk of bleeding.
@en
type
label
Selective depletion of plasma ...... ut increased risk of bleeding.
@en
prefLabel
Selective depletion of plasma ...... ut increased risk of bleeding.
@en
P2093
P2860
P1433
P1476
Selective depletion of plasma ...... ut increased risk of bleeding.
@en
P2093
A Robert MacLeod
Alexey S Revenko
Brett P Monia
Chenguang Zhao
David Gailani
Gourab Bhattacharjee
Jeff R Crosby
P2860
P304
P356
10.1182/BLOOD-2011-05-355248
P407
P577
2011-08-05T00:00:00Z